About The GLP-1 Daily
The GLP-1 Daily provides evidence-based coverage of GLP-1 receptor agonist medications, weight management research, and treatment options. We help readers make informed decisions about semaglutide, tirzepatide, and other GLP-1 drugs by analyzing clinical data, comparing programs, and explaining costs transparently.
Our Editorial Process
Every article is researched using clinical trials, FDA data, peer-reviewed studies, and verified pricing information. Our content is AI-assisted and human-curated to ensure accuracy, clarity, and balance.
- We cite primary sources wherever possible
- We disclose affiliate relationships transparently
- We never make medical claims or guarantee outcomes
- We update articles as new research and pricing data becomes available
Medical Disclaimer
The GLP-1 Daily is an informational resource, not a medical provider. Our content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before starting, stopping, or changing any medication.
Affiliate Disclosure
Some links on this site are affiliate links. We may earn a commission if you make a purchase through these links, at no extra cost to you. This helps support our research and keeps our content free. Our reviews and recommendations are independent — affiliate relationships never influence our editorial judgment.
Contact
Have questions, corrections, or feedback? We'd love to hear from you. Reach us at hello@theglp1daily.com.